Skip to main content

Anaptysbio, Inc

ANAB
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001370053

No open-market purchases or sales by Anaptysbio, Inc insiders were filed in the last 90 days; 213 institutions reported holding it in 13F filings for Q2 2026, worth $2.03B in total; no superinvestor holds it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Anaptysbio, Inc insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
0 filings
Insiders trading
0
Net value
$0
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Anaptysbio, Inc, current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Anaptysbio, Inc
NameTitleLast reported holdingLast filingFilings, past year
Orwin John ADirector17,995Sep 17, 20264
Lizzul Paul F.Chief Medical Officer42,088Aug 7, 20265
Faga DanielPresident, CEO495,965Aug 7, 20266
Renton HollingsDirector10,995Jun 17, 20263
Schmid John P.Director37,652Jun 17, 20265
Hughes OwenDirector–May 13, 20261
Murphy Christopher M.Chief Financial Officer–May 13, 20261
Gray SusannahDirector–Apr 29, 20261
Loumeau Eric JCHIEF LEGAL OFFICER12,835Feb 13, 20267
Marquet MagdaDirector9,930Jan 16, 20262
Mulroy DennisCHIEF FINANCIAL OFFICER21,852Jan 9, 20265
Fenton Dennis MDirector4,965Jan 8, 20261
Jain RitaDirector11,864Jan 8, 20261
Ware J. AnthonyDirector9,630Jan 8, 20262
Nodelman OlegDirector, 10% Owner7,880,094IndirectJan 2, 20250
EcoR1 Capital, LLCDirector, 10% Owner7,880,094IndirectJan 2, 20250
Topper James NDirector, 10% Owner–Jan 10, 20230
Hamill LauraDirector–Jan 10, 20230
Suria HamzaPresident, CEO68,600Feb 14, 20220

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Sep 18, 2023 (view filing)Sep 14-184 daysMulroy DennisChief Financial OfficerSSale−6.00K$19.38−$116.3K−86.2%964 after2 lots
Aug 9, 2022 (view filing)Aug 81 dayLoumeau Eric JCOO, General CounselSSale−523$25.00−$13.1K−100.0%0 after
Jun 10, 2022 (view filing)Jun 82 daysLoumeau Eric JCOO, General CounselSSale−2.50K$24.00−$60.0K−82.7%523 after
May 20, 2022 (view filing)May 182 daysLoumeau Eric JCOO, General CounselSSale−1.15K$20.50−$23.5K−68.7%523 after
May 9, 2022 (view filing)6:04 AM ETMay 54 daysNodelman Oleg and 1 otherDirector, 10% OwnerPPurchase+668.2K$21.63+$14.5M+9.8%7.52M after
May 9, 2022 (view filing)6:04 AM ETMay 54 daysNodelman Oleg and 1 otherDirector, 10% OwnerSSale−668.2K$21.63−$14.5M−8.2%7.52M after
Dec 22, 2021 (view filing)Dec 202 daysSuria HamzaPresident, CEOSSale−36.6K$35.57−$1.30M−34.8%68.6K after3 lots
Nov 5, 2021 (view filing)Nov 4-51 daySuria HamzaPresident, CEOSSale−20.4K$35.00−$712.6K−23.1%67.6K after2 lots
Nov 5, 2021 (view filing)Nov 41 dayLoumeau Eric JCOO, General CounselSSale−5.00K$35.00−$175.0K−100.0%0 after
Nov 2, 2021 (view filing)Nov 11 daySuria HamzaPresident, CEOSSale−36.6K$32.31−$1.18M−35.1%67.6K after2 lots
Oct 28, 2021 (view filing)Oct 262 daysSuria HamzaPresident, CEOSSale−16.0K$30.00−$479.8K−19.1%67.6K after